Cargando…

Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research

Risk Group 4 pathogens are a group of often lethal human viruses for which there are no widely available vaccines or therapeutics. These viruses are endemic to specific geographic locations and typically cause relatively infrequent, self-limiting, but often devastating human disease outbreaks (e.g....

Descripción completa

Detalles Bibliográficos
Autores principales: Logue, James, Solomon, Jeffrey, Niemeyer, Brian F., Benam, Kambez H., Lin, Aaron E., Bjornson, Zach, Jiang, Sizun, McIlwain, David R., Nolan, Garry P., Palacios, Gustavo, Kuhn, Jens H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122670/
http://dx.doi.org/10.1007/978-3-030-29022-1_15
_version_ 1783515469329727488
author Logue, James
Solomon, Jeffrey
Niemeyer, Brian F.
Benam, Kambez H.
Lin, Aaron E.
Bjornson, Zach
Jiang, Sizun
McIlwain, David R.
Nolan, Garry P.
Palacios, Gustavo
Kuhn, Jens H.
author_facet Logue, James
Solomon, Jeffrey
Niemeyer, Brian F.
Benam, Kambez H.
Lin, Aaron E.
Bjornson, Zach
Jiang, Sizun
McIlwain, David R.
Nolan, Garry P.
Palacios, Gustavo
Kuhn, Jens H.
author_sort Logue, James
collection PubMed
description Risk Group 4 pathogens are a group of often lethal human viruses for which there are no widely available vaccines or therapeutics. These viruses are endemic to specific geographic locations and typically cause relatively infrequent, self-limiting, but often devastating human disease outbreaks (e.g. Ebola virus, Kyasanur Forest disease virus, Lassa virus). The overall rarity of disease outbreaks with the associated lack of clinical data and the requirement for research on Risk Group 4 pathogens to be performed in maximum (biosafety level 4) containment necessarily impede progress in medical countermeasure development. Next-generation technologies may aid to bridge the current gaps of knowledge by increasing the amount of useful data that can be gleaned from individual diagnostic samples, possibly even at point-of-care; enable personalized medicine approaches through genomic virus characterization in the clinic; refine our comprehension of pathogenesis by using ex vivo technologies such as organs-on-chips or organoids; identify novel correlates of protection or disease survival that could inform novel medical countermeasure development; or support patient and treatment response monitoring through non-invasive techniques such as medical imaging. This chapter provides an overview of a subset of such technologies and how they may positively impact the field of Risk Group 4 pathogen research in the near future.
format Online
Article
Text
id pubmed-7122670
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71226702020-04-06 Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research Logue, James Solomon, Jeffrey Niemeyer, Brian F. Benam, Kambez H. Lin, Aaron E. Bjornson, Zach Jiang, Sizun McIlwain, David R. Nolan, Garry P. Palacios, Gustavo Kuhn, Jens H. Global Virology III: Virology in the 21st Century Article Risk Group 4 pathogens are a group of often lethal human viruses for which there are no widely available vaccines or therapeutics. These viruses are endemic to specific geographic locations and typically cause relatively infrequent, self-limiting, but often devastating human disease outbreaks (e.g. Ebola virus, Kyasanur Forest disease virus, Lassa virus). The overall rarity of disease outbreaks with the associated lack of clinical data and the requirement for research on Risk Group 4 pathogens to be performed in maximum (biosafety level 4) containment necessarily impede progress in medical countermeasure development. Next-generation technologies may aid to bridge the current gaps of knowledge by increasing the amount of useful data that can be gleaned from individual diagnostic samples, possibly even at point-of-care; enable personalized medicine approaches through genomic virus characterization in the clinic; refine our comprehension of pathogenesis by using ex vivo technologies such as organs-on-chips or organoids; identify novel correlates of protection or disease survival that could inform novel medical countermeasure development; or support patient and treatment response monitoring through non-invasive techniques such as medical imaging. This chapter provides an overview of a subset of such technologies and how they may positively impact the field of Risk Group 4 pathogen research in the near future. 2019-11-23 /pmc/articles/PMC7122670/ http://dx.doi.org/10.1007/978-3-030-29022-1_15 Text en © Springer Nature Switzerland AG 2019 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Logue, James
Solomon, Jeffrey
Niemeyer, Brian F.
Benam, Kambez H.
Lin, Aaron E.
Bjornson, Zach
Jiang, Sizun
McIlwain, David R.
Nolan, Garry P.
Palacios, Gustavo
Kuhn, Jens H.
Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title_full Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title_fullStr Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title_full_unstemmed Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title_short Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research
title_sort innovative technologies for advancement of who risk group 4 pathogens research
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122670/
http://dx.doi.org/10.1007/978-3-030-29022-1_15
work_keys_str_mv AT loguejames innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT solomonjeffrey innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT niemeyerbrianf innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT benamkambezh innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT linaarone innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT bjornsonzach innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT jiangsizun innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT mcilwaindavidr innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT nolangarryp innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT palaciosgustavo innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch
AT kuhnjensh innovativetechnologiesforadvancementofwhoriskgroup4pathogensresearch